Similar Search Results

NICE Cost-Effectiveness Appraisal of Cholinesterase Inhibitors: Was the Right Question Posed? Were the Best Tools Used?

Getsios, Denis; Migliaccio-Walle, Kristen; Caro, Jaime J. - In: PharmacoEconomics 25 (2007) 12, pp. 997-1006

modelling technologies, basing analyses on a limited subset of the available data, and insufficiently reflecting the uncertainty …

Persistent link: https://www.econbiz.de/10005243114

Modelling Disease Progression in Alzheimer's Disease: A Review of Modelling Methods used for Cost-Effectiveness Analysis

Green, Colin - In: PharmacoEconomics 25 (2007) 9, pp. 735-750

considered in more detail. The review employs recent guidance on good practice in decision-analytic modelling in HTA to … critically review the modelling methods used. Using this guidance, the models are assessed against the broad criteria of model … the basis for the modelling of treatment effects. It is also clear that studies modelling AD progression, and subsequently …

Persistent link: https://www.econbiz.de/10005404907

Modelling Downstream Effects in the Presence of Technological Change

Mortimer, Duncan - In: PharmacoEconomics 26 (2008) 12, pp. 991-1003

Downstream effects are typically evaluated given current technology and current practice patterns rather than for technology and practice patterns that will be available at the time when downstream effects accrue. Where a relatively short time horizon can be expected to capture all relevant...

Persistent link: https://www.econbiz.de/10005449087

Modelling the Ability of Risk Adjusters to Reduce Adverse Selection in Managed Care

Stafford, Randall S.; Li, Donglin; Davis, Roger B.; … - In: Applied Health Economics and Health Policy 3 (2004) 2, pp. 107-114

Population-based risk adjustment, as applied to reimbursement in managed care settings, may reduce pressures for adverse selection by managed care organisations. Using insurance claims data from 184

Persistent link: https://www.econbiz.de/10005243066

Using Policy Simulation to Predict Drug Plan Expenditure when Planning Reimbursement Changes

Dormuth, Colin R.; Burnett, Sean; Schneeweiss, Sebastian - In: PharmacoEconomics 23 (2005) 10, pp. 1021-1030

Background: Drug plan decision makers need accurate financial impact projections before the implementation of new drug policy initiatives. Tools for such projections need to have small margins of error and be based on methodology that is easy to communicate to stakeholders. Ad hoc methods...

Persistent link: https://www.econbiz.de/10005448972

Demand Forecasting for Preventive AIDS Vaccines: Economic and Policy Dimensions

Hecht, Robert; Gandhi, Gian - In: PharmacoEconomics 26 (2008) 8, pp. 679-697

Background: An AIDS vaccine could play a very significant role in reversing the HIV pandemic, saving millions of lives. For a vaccine to have such an impact, it must be widely available and adopted and taken up rapidly in the countries most affected. A demand-forecasting model provides a...

Persistent link: https://www.econbiz.de/10005590485

Continuous Time Simulation and Discretized Models for Cost-Effectiveness Analysis

Soares, Marta O.; Canto e Castro, Lusa - In: PharmacoEconomics 30 (2012) 12, pp. 1101-1117

The design of decision-analytic models for cost-effectiveness analysis has been the subject of discussion. The current work addresses this issue by noting that, when time is to be explicitly modelled, we need to represent phenomena occurring in continuous time. Models evaluated in continuous...

Persistent link: https://www.econbiz.de/10011005076

Selecting a Mix of Prevention Strategies against Cervical Cancer for Maximum Efficiency with an Optimization Program

Demarteau, Nadia; Breuer, Thomas; Standaert, Baudouin - In: PharmacoEconomics 30 (2012) 4, pp. 337-353

Background:Background: Screening and vaccination against human papillomavirus (HPV) can protect against cervical cancer. Neither alone can provide 100% protection. Consequently it raises the important question about the most efficient combination of screening at specified time intervals and...

Persistent link: https://www.econbiz.de/10009653279

Population- versus Cohort-Based Modelling Approaches

Ethgen, Olivier; Standaert, Baudouin - In: PharmacoEconomics 30 (2012) 3, pp. 171-181

While no single type of model can provide adequate answers under all circumstances, any modelling endeavour should … are essentially two different approaches in modelling a population over time: a cohort-based approach and a population …

Persistent link: https://www.econbiz.de/10009493378

Economic Evaluation of Smoking-Cessation Therapies: A Critical and Systematic Review of Simulation Models

Bolin, Kristian - In: PharmacoEconomics 30 (2012) 7, pp. 551-564

mathematical modelling (both deterministic and stochastic) of future events important for cost effectiveness. Abstract: Objectives …:Objectives: This study surveys cost-effectiveness analyses of smoking cessation, with a particular focus on the mathematical modelling … modelling. Abstract: Conclusions:Conclusions: In general, studies are well performed as regards modelling. Common weaknesses …

Persistent link: https://www.econbiz.de/10010551729

1
2
3
4
5
6
7
8
9
10
Next
Last